These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29403383)

  • 21. [Pharmacological cognitive enhancement from a perspective of misuse and addiction].
    Franke AG; Soyka M
    Fortschr Neurol Psychiatr; 2015 Feb; 83(2):83-90. PubMed ID: 25723772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review.
    Battleday RM; Brem AK
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):1865-81. PubMed ID: 26381811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The polysemy of psychotropic drugs: continuity and overlap between neuroenhancement, treatment, prevention, pain relief, and pleasure-seeking in a clinical setting.
    Sakakibara E
    BMC Med Ethics; 2020 Jul; 21(1):54. PubMed ID: 32631307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Complexity of Neuroenhancement and the Adoption of a Social Cognitive Perspective.
    Zelli A; Lucidi F; Mallia L
    Front Psychol; 2015; 6():1880. PubMed ID: 26648906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Use and Impact of Cognitive Enhancers among University Students: A Systematic Review.
    Sharif S; Guirguis A; Fergus S; Schifano F
    Brain Sci; 2021 Mar; 11(3):. PubMed ID: 33802176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pills or Push-Ups? Effectiveness and Public Perception of Pharmacological and Non-Pharmacological Cognitive Enhancement.
    Caviola L; Faber NS
    Front Psychol; 2015; 6():1852. PubMed ID: 26696922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological Neuroenhancement: Current Aspects of Categorization, Epidemiology, Pharmacology, Drug Development, Ethics, and Future Perspectives.
    Daubner J; Arshaad MI; Henseler C; Hescheler J; Ehninger D; Broich K; Rawashdeh O; Papazoglou A; Weiergräber M
    Neural Plast; 2021; 2021():8823383. PubMed ID: 33519929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Case of Pharmacological Neuroenhancement: Medical, Judicial and Ethical Aspects from a German Perspective.
    Franke AG; Northoff R; Hildt E
    Pharmacopsychiatry; 2015 Nov; 48(7):256-64. PubMed ID: 26252723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A survey of substance use for cognitive enhancement by university students in the Netherlands.
    Schelle KJ; Olthof BM; Reintjes W; Bundt C; Gusman-Vermeer J; van Mil AC
    Front Syst Neurosci; 2015; 9():10. PubMed ID: 25741248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The brain as an agentic system: how the brain is articulated in the field of neuroenhancement.
    Brenninkmeijer J
    Sociol Health Illn; 2019 Jan; 41(1):112-127. PubMed ID: 30155996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attitudes toward pharmacological cognitive enhancement-a review.
    Schelle KJ; Faulmüller N; Caviola L; Hewstone M
    Front Syst Neurosci; 2014; 8():53. PubMed ID: 24860438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of methylphenidate among students: the future of enhancement?
    Outram SM
    J Med Ethics; 2010 Apr; 36(4):198-202. PubMed ID: 20338928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroenhancement: enhancing brain and mind in health and in disease.
    Clark VP; Parasuraman R
    Neuroimage; 2014 Jan; 85 Pt 3():889-94. PubMed ID: 24036352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive enhancers versus addictive psychostimulants: The good and bad side of dopamine on prefrontal cortical circuits.
    Bisagno V; González B; Urbano FJ
    Pharmacol Res; 2016 Jul; 109():108-18. PubMed ID: 26826399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review.
    Repantis D; Laisney O; Heuser I
    Pharmacol Res; 2010 Jun; 61(6):473-81. PubMed ID: 20193764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The importance of stress, self-efficacy, and self-medication for pharmacological neuroenhancement among employees and students.
    Maier LJ; Haug S; Schaub MP
    Drug Alcohol Depend; 2015 Nov; 156():221-227. PubMed ID: 26455555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroenhancement for sale: assessing the website claims of neurofeedback providers in the United States.
    Wexler A; Nagappan A; Kopyto D; Choi R
    J Cogn Enhanc; 2020 Dec; 4(4):379-388. PubMed ID: 34164596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Performance enhancement at the cost of potential brain plasticity: neural ramifications of nootropic drugs in the healthy developing brain.
    Urban KR; Gao WJ
    Front Syst Neurosci; 2014; 8():38. PubMed ID: 24860437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic review.
    Fond G; Micoulaud-Franchi JA; Brunel L; Macgregor A; Miot S; Lopez R; Richieri R; Abbar M; Lancon C; Repantis D
    Psychiatry Res; 2015 Sep; 229(1-2):12-20. PubMed ID: 26187342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prevalence of pervasive developmental disorders. A review].
    Lenoir P; Bodier C; Desombre H; Malvy J; Abert B; Ould Taleb M; Sauvage D
    Encephale; 2009 Feb; 35(1):36-42. PubMed ID: 19250992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.